Bevacizumab, bleeding, thrombosis, and warfarin

Journal of Clinical Oncology

Volumn 21, Issue 18, 2003, Pages 3542-

  Kilickap, Saadettin ^a   Abali, Hüseyin ^a   Celik, Ismail ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; BEVACIZUMAB; ENDOTHELIAL CELL GROWTH FACTOR; FLUOROURACIL; FOLINIC ACID; LYMPHOKINE; MONOCLONAL ANTIBODY; SIGNAL PEPTIDE; VASCULOTROPIN; VASCULOTROPIN A; WARFARIN;

BLEEDING; CHEMICALLY INDUCED DISORDER; COLORECTAL TUMOR; HUMAN; IMMUNOLOGY; METASTASIS; NOTE; PATHOLOGY; THROMBOSIS;

ANTIBODIES, MONOCLONAL; ANTICOAGULANTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; ENDOTHELIAL GROWTH FACTORS; FLUOROURACIL; HEMORRHAGE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LEUCOVORIN; LYMPHOKINES; NEOPLASM METASTASIS; THROMBOSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS; WARFARIN;

EID: 0142121282     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2003.99.046     Document Type: Letter

References (4)

1. Kabbinavar F, Hurwitz H, Fehrenbacher L, et al: Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leocovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21: 60-65, 2003
2. Maragoudakis ME, Tsopanoglou NE, Andriopoulou P: Mechanism of thrombin-induced angiogenesis. Biochem Soc Trans 30: 173-177, 2002
3. Haroon Z, Amin K, Saito W, et al: SU5416 delays wound healing through inhibition of TGF-beta 1 activation. Cancer Biol Ther 1: 121-126, 2002
4. Kolesar J, Johnson J, Freeberg B, et al: Warfarin-5-FU interaction: A consecutive case series. Pharmacotherapy 19: 1445-1449, 1999